OncoDNA
THE CANCER THERANOSTIC COMPANY

Introduction to the Molecular Diagnostic Innovation Partnership

Learnings from working with the health sector to date…

- Reimbursement processes are not easy for clinicians and patients to navigate (in both the NHS and private sector)
  - In the private sector the challenge is amplified because the clinician is not directly employed by the private provider
  - Clinicians in the private and public sectors often only request molecular profiling when treatment options are running out
  - Only a limited group of clinical innovators are accessing molecular diagnostics
- Insurers historically have declined testing, pushing patients to pay out of pocket
  - The *Letter of Necessity* is not standardised within the sector and consumes clinical time to generate
- More work is needed to educate the oncology community around the utility of molecular diagnostics
  - Patients also need education on what to expect before, during and after molecular testing
- There is a lot of variation with insufficient data to track how much testing is really taking place
  - More UK based studies are needed to support the use of genomic testing in routine cancer care

Responding to these learnings, we have committed to building an ecosystem that will:

- ✓ Educate oncologists, helping them make choices about molecular testing for their patients
- ✓ Educate patients so they can appropriately consent to testing
- ✓ Make the complex process of testing easy
- ✓ Support the oncologist and MDT to use insights from molecular testing to personalise treatment decisions for their patients
- ✓ Embed molecular diagnostics into routine clinical care
- ✓ Signpost oncologists and their patients to clinical trials where appropriate
- ✓ Empower patients to collect outcome data and share this with their oncologist
- ✓ Build out the evidence case for molecular testing
- ✓ Bond partners together from across industry and pharma to support innovation for the benefit of patients

Introducing the Molecular Diagnostic Innovation Partnership (MDIP)…

The MDIP is a problem-solving ecosystem, bringing together care providers, payors and industry representatives to overcome barriers to the adoption of biomarker testing in cancer.

MDIP Mission Statement

- Support MDIP partners in all aspects of the biomarker testing pathway, including patient access, reimbursement, test selection and interpretation of results.
- Define, document and disseminate best practice in biomarker testing through the MDIP network and beyond through publication and other media.
- Provide educational materials appropriate for medical professions and patients living with cancer.

The MDIP will attract a wide range of stakeholders

Care providers	Diagnosticians	Clinicians	Patients	Payors
• Specialists nurses • Managers	• Pathologists • Clinical scientists	• Oncologists • Surgeons • Academics	• Representatives • Advocacy groups	• Insurers • Charities • Patients (out of pocket)

Technology Vendors and Pharma



The MDIP will enhance connectivity within and between organisations and sectors providing an opportunity to collectively influence and shape policy and practice in genomics

- Education
- Pathways & processes
- Outreach
- Defining best practice
- Information exchange
- **Making precision oncology a reality**

OncoDNA
THE CANCER THERANOSTIC COMPANY

Benefits of the MDIP for providers, payors, clinicians & patients

	Test availability	Test ordering	MDT review	Result annotation	Monitoring & retesting
Pain points	Funding of tests Patient eligibility Care pathway position	Ordering process Tissue availability Most appropriate test	Genomic data Other biomarker data Clinical utility	Physician expectations Patient expectations Clinical outcome	Which test How often Clinical utility
MDIP support	**Harmonisation** **National platform** **Usage data collection**	**Pathway redesign** **Pathology support** **Clinical support**	**Data insights** **Clinical interpretation** **Clinical trial search**	**Physician support** **Patient outreach** **Educational materials**	**Clinical education** **Patient involvement** **CPD provision**

The MDIP will help UK healthcare (private and public) to grow the use of genomics

- National forum for shaping practice
- Increased testing and reporting capacity
- Enhanced access to molecular testing
- Genomic upskilling of the MDT team
- Accelerated adoption of best practices
- Benchmarking across the sectors

OncoDNA
THE CANCER THERANOSTIC COMPANY

The MDIP roadmap

Test out our ideas	Firm up our plans	Soft launch	National Meeting	Grow the Membership
• Share our plans	• Secure early adopters	• Talk about our work more widely	• First national conference *(COVID permitting)*	• Solid foundation for the MDIP created
May – June 2020	June- September 2020	November 2020	November 2021	December 2021

Governance of the MDIP

MDIP Governance Structure

The MDIP will run as an autonomous organisation, underpinned by collaborative partnerships between different stakeholders. Operational aspects of the MDIP will be supported by the OncoDNA MDIP team, under the leadership of the OncoDNA UK country lead. The strategic focus of the MDIP will be directed by the Strategic Advisory Board (SAB), whose recommendations will be relayed to the OncoDNA MDIP team.

MDIP Strategic Advisory Board (SAB) Membership

The SAB will consist of 7-12 members:

- 1-2 oncologists
- 1-2 pathologists or consultant clinical scientists
- 1-2 clinical nurse specialists
- 1-2 representatives from the insurance sector
- 1-2 patient representatives
- 1-2 academics with expertise in cancer genomics (physician or scientist)
- 1 representative from OncoDNA

Working groups will be formed from different segments of MDIP membership to influence and lead change; currently we expect these to be focused on:

- Private payors (health insurers)
- NHS payors (commissioners)
- Bringing suppliers together (BIVDA)
- Patient education (patients)
- Clinical pathways (oncologists)
- Accademia (universities)
- Pharma (this is a longer term subgroup; not in the first year)

We propose that the BIVDA Genomics group becomes the working group representing industry within the MDIP

This will leverage the work started already by OncoDNA and bring the industry voice into the MDIP ecosystem so that collectively we can solve the challenges of embedding genomics in routine cancer care.



Any organisation that joins the MDIP ahead of the first national conference (October 2021) will be invited to add their brand to the launch film.
The film will be used to open the conference evidencing the commitment of multiple stakeholders to bond together to transform care for the benefit of patients

Contact Amanda.bassett@oncodna.com

OncoDNA
THE CANCER THERANOSTIC COMPANY